Medtronic Announces Real-World Registry Results For Its Affera Mapping And Ablation System With The Sphere-9 Catheter And The PulseSelect Pulsed Field Ablation System; Analyses Report Strong Safety And Procedural Outcomes Across Atrial And Ventricular Arrhythmias
The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia
Medtronic's heart rhythm tools showed good safety and success rates in real patient use. When a company proves its medical devices work well in the real world, investors watch for growing doctor trust.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.